Little Green Pharma (ASX:LGP) receives manufacturing permit


11 May 2020

Approved stamp image
Little Green Pharma has been granted a new manufacturing permit from the office of drug control

Medicinal cannabis company, Little Green Pharma (LGP) has been granted a new manufacturing permit from the office of drug control.

The manufacturing permit will allow the company to manufacture cannabis extracts for holders of therapeutic goods administration (TGA) GMP manufacturing licences to produce medicinal cannabis products.

Little Green has an exclusive agreement with its GMP-licenced manufacturing partner to produce the products.

The permit is valid for one year and ends in March 2021. This new permit will also allow the company to commence in-house extraction once the next crop is harvested, which is set to reduce costs and improve efficiencies.

Managing Director Fleta Solomon said receiving this permit also gives the company the capability to manufacture cannabis extracts at its manufacturing premises.

"We are now only waiting for our expanded ODC Medicinal Cannabis Cultivation and Production Permit which, once granted, will allow us to begin first planting at our expanded cultivation facility and to significantly expand our production operations," she said.

Read the full article by Lisa Simcock, Markets Reporter here:

You might also be interested in

Grow room expansion


Commissioning of cultivation facility expansion complete

On-time and on budget. Read more about our expansion facility here.

Mar 2020

Team pic

Company news

Ring The Bell
Empowering a growing team to build a global brand

Nov 2020

STATS 150321 News 1400x1400

Regulatory News

Industry Update: February 2021
The Therapeutic Goods Administration (TGA), has set its largest month on record for Medicinal cannabis approvals.

Mar 2021

View all articles